Chief Commercial Officer (CCO) Peter Nordkild has resigned his position in
Pharmexa to accept the position as CEO in the Danish biotech company Egalet.
Peter Nordkild's responsibilities will until further notice be taken over by
Chief Executive Officer Jakob Schmidt.
Hørsholm, August 23, 2007
Jakob Schmidt
Chief Executive Officer
Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45
4516 2525
Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45
4060 2558
Note to editors: Pharmexa A/S is a leading company in the field of active
immunotherapy and vaccines for the treatment of cancer, serious chronic and
infectious diseases. Pharmexa's proprietary technology platforms are broadly
applicable, allowing the company to address critical targets in cancer, bone
degeneration and Alzheimer's disease, as well as serious infectious diseases
such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001,
a peptide vaccine that has entered phase III trials in pancreatic cancer and
phase II trials in liver cancer, and HIV and hepatitis vaccines in phase I/II.
Collaborative agreements include H. Lundbeck, Innogenetics, ImmunoVaccine
Technologies and Bavarian Nordic. With operations in Denmark, Norway and USA,
Pharmexa employs approximately 105 people and is listed on the Copenhagen Stock
Exchange under the trading symbol PHARMX.
